Entering text into the input field will update the search result below

FENC Fennec Pharmaceuticals Inc.
Stock Price & Overview

$7.510.36 (+5.03%)3:59 PM 09/29/23
NASDAQ | $USD | Post-Market: $7.51 6:06 PM

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

Now6M ago
SA Analysts
Not CoveredRating: Not Covered
Wall Street
Not CoveredRating: Not Covered
Quant
Not CoveredRating: Not Covered

Ratings Summary

SA Analysts
Wall Street
Quant
Now3M ago6M ago
Valuation
-Rating: Not Covered
Growth
-Rating: Not Covered
Profitability
-Rating: Not Covered
Momentum
-Rating: Not Covered
Revisions
-Rating: Not Covered

See FENC ratings with Premium.

Company Profile

Fennec Pharmaceuticals Inc. logo
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company’s product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Employees
36
Founded
1996
Address
  • 68 TW Alexander Drive
  • PO Box 13628
  • Research Triangle Park, NC, 27709
  • United States
Phone Number
919 636 4530
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.